ArticleJournal of thoracic disease2025
Duration of extracorporeal membrane oxygenation support and survival outcomes: a retrospective analysis for lung transplant recipients with idiopathic pulmonary fibrosis.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung transplantation (LTx) is the only effective treatment for patients with end-stage idiopathic pulmonary fibrosis (IPF). However, little is known about the effect of extracorporeal membrane oxygenation (ECMO) on the prognosis of these patients. This study aimed to explore the association between ECMO duration and survival outcomes in IPF patients undergoing LTx. Methods: This was a single-center retrospective cohort study that included 276 IPF patients who underwent LTx at the Affiliated Wuxi People's Hospital of Nanjing Medical University China, between January 2015 and December 2020. The primary outcome was overall survival (OS). Several Cox proportional hazards regression models with a cubic spline function were established to analyze the association between ECMO duration and mortality. Results: Among the 276 recipients, the median duration of ECMO was 24 hours [interquartile range (IQR): 7.25-40.0 hours], with 80 (29.0%) receiving veno-arterial (VA) ECMO support, 149 (54.0%) receiving veno-venous (VV) ECMO support, and 47 (17.0%) not receiving any ECMO support. There was no statistically significant difference in cumulative survival among the ECMO support strategies (P=0.44). The main model showed a 13% increase in mortality risk for each additional day of ECMO use [hazard ratio (HR) =1.13, 95% confidence interval (CI): 1.07-1.20, P<0.001]. The continuous relationship between ECMO duration and mortality risk revealed a nonlinear association (P-overall ≤0.001; P-nonlinear =0.002), with 0.8 and 5.54 days identified as cutoff values. Conclusions: In IPF patients receiving LTx, ECMO duration demonstrates a strong nonlinear association with mortality. Longer duration of ECMO support serves as a robust indicator of underlying disease severity and postoperative complications predicting poor outcomes. The identified thresholds (0.8 and 5.54 days) provide clinically relevant markers for risk stratification and prognostication. Future prospective studies are needed to validate these inflection points and clarify interactions between ECMO duration, patient factors, and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.